US firm Biogen has upgraded its guidance for the financial year and now predicts a higher revenue than originally expected, Bloomberg News writes based on the company's Q2 report.
The pharmaceutical company now predicts a revenue of between USD 10.65bn and USD 10.85bn, compared to its previous expectation of between USD 10.45bn and USD 10.75bn. The analyst consensus estimate was a USD 10.59bn revenue.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.